Results 221 to 230 of about 16,895 (259)
Some of the next articles are maybe not open access.
Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin
Biochemical Journal, 2002Neprilysin (NEP) 2 is a recently cloned glycoprotein displaying a high degree of sequence identity with neprilysin (EC 3.4.24.11), the prototypical member of the M13 subfamily of metalloproteases. Whereas NEP is involved in the metabolism of several bioactive peptides by plasma membranes of various cells, the enzymic properties and physiological ...
Christiane, Rose +4 more
openaire +2 more sources
Angiotensin Receptor Neprilysin Inhibitors—2019 Update
Cardiovascular Drugs and Therapy, 2020An abundance of new data regarding the use of the novel drug compound sacubitril/valsartan in chronic heart failure (CHF) patients is published every year since the initial publication of the PARADIGM-HF study in 2014. This review summarises the most recent evidence (2019 and onwards) of sacubitril/valsartan in CHF patients as well as provides a ...
George Chalikias, Dimitrios Tziakas
openaire +2 more sources
Neprilysin Regulates Amyloid β Peptide Levels
Journal of Molecular Neuroscience, 2004That neprilysin (NEP) is a major Abeta peptide-degrading enzyme in vivo is shown by higher Abeta peptide levels in the brain of an NEP knockout mouse. In addition, we show that infusion of an NEPinhibitor, but not inhibitors of other peptidases, into the brains of an APP transgenic mouse elevates Abeta levels.
Robert A, Marr +7 more
openaire +2 more sources
Neprilysin and Amyloid Beta Peptide Degradation
Current Alzheimer Research, 2008Neprilysin is a zinc metalloendopeptidase with relatively broad substrate specificity. The enzyme is localized to the plasma membrane of cells where it can function to degrade extracellular peptides. Structural studies show that neprilysin preferentially cleaves peptides on the amino side of hydrophobic amino acids.
Louis B, Hersh, David W, Rodgers
openaire +2 more sources
Dual-Acting Angiotensin Receptor–Neprilysin Inhibition
Current Hypertension Reports, 2010Lowering blood pressure by pharmacologic intervention reduces the incidence of cardiovascular events. Nevertheless, despite the widespread availability of effective antihypertensive medications, the vast majority of hypertensive patients worldwide continue to have inadequate blood pressure control.
Julian, Segura, Luis M, Ruilope
openaire +2 more sources
Convoluted molecular maze of neprilysin
Diagnosis, 2022Eleftherios P. Diamandis +2 more
openaire +2 more sources
Angiotensin receptor-neprilysin inhibitors
Abstract The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan is a first-line agent for all patients with heart failure and reduced ejection fraction (LVEF). Sacubitril/valsartan is well-tolerated and, in comparison to angiotensin-converting enzyme (ACE) inhibitor therapy, has been shown to reduce both morbidity ...Roy S. Gardner +3 more
openaire +1 more source
Neprilysin Inhibition for Heart Failure
New England Journal of Medicine, 2014John J V, McMurray +2 more
openaire +5 more sources